Literature DB >> 646234

Adenoacanthoma of the pancreas: report of four cases and literature review.

S Weitzner.   

Abstract

Cases of 20 patients with adenoacenthoma of the pancreas with clinicopathologic data, including the four added, are reviewed. The clinical manifestations, sites of metastases, survival and gross pathology appear to be similar to the usual adenocarcinoma of the pancreas. Adenoacanthoma of the pancreas most probably represents squamous metaplasia of an adenocarcinoma or arises from an undifferentiated cell in the pancreatic duct system. The metastases are typically an admixture of both elements but in four cases, pure squamous or adenocarcinoma metastases were encountered. It is suggested that the pancreas should be included as a possible source in those patients with an unknown primary who have a metastasis consisting of either an admixture of squamous and glandular elements or a pure squamous type and in those instances in which a pure squamous and a pure adenocarcinoma are encountered in different metastases.

Entities:  

Mesh:

Year:  1978        PMID: 646234

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  3 in total

1.  Adenosquamous carcinoma of the pancreas.

Authors:  G V Aranha; S Yong; M Olson
Journal:  Int J Pancreatol       Date:  1999-10

2.  415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival.

Authors:  Casey A Boyd; Jaime Benarroch-Gampel; Kristin M Sheffield; Catherine D Cooksley; Taylor S Riall
Journal:  J Surg Res       Date:  2011-07-07       Impact factor: 2.192

3.  Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy.

Authors:  Kotaro Shibagaki; Koichi Fujita; Shinji Nakayama; Mamoru Takenaka; Nobuhiko Fukuba; Saori Matsui; Masato Ozaka; Hiroshi Yoshinaga; Akira Masuzawa; Akihiko Watanabe; Hitoshi Fujiwara; Atsushi Sugawara; Tsuyoshi Fujita; Hidekazu Mukai; Yoshikazu Kinoshita
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.